C

China National Medicines Corp Ltd
SSE:600511

Watchlist Manager
China National Medicines Corp Ltd
SSE:600511
Watchlist
Price: 28.63 CNY 2.03% Market Closed
Market Cap: ¥21.6B

China National Medicines Corp Ltd
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

China National Medicines Corp Ltd
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
C
China National Medicines Corp Ltd
SSE:600511
Research & Development
-¥73.2m
CAGR 3-Years
-7%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
Sinopharm Group Co Ltd
HKEX:1099
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Research & Development
-¥2.3B
CAGR 3-Years
-5%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Jointown Pharmaceutical Group Co Ltd
SSE:600998
Research & Development
-¥146.3m
CAGR 3-Years
10%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Huadong Medicine Co Ltd
SZSE:000963
Research & Development
-¥2B
CAGR 3-Years
-24%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
C
China National Accord Medicines Corp Ltd
SZSE:000028
Research & Development
-¥21.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

China National Medicines Corp Ltd
Glance View

Market Cap
21.6B CNY
Industry
Health Care

China National Medicines Corp Ltd., often known as Sinopharm Group's public face, is a leviathan in the realm of pharmaceutical distribution. Headquartered in Beijing, this company is deeply entrenched in the layers of China's healthcare system. Its operations are woven through a vast network that includes the wholesale and retail distribution of an extensive range of pharmaceutical products. The company prides itself on streamlining the supply chain, connecting pharmaceutical manufacturers directly with hospitals, clinics, and pharmacies. By leveraging its logistical expertise and expansive reach, Sinopharm ensures that essential medicines flow seamlessly from producers to end-users, maintaining the vital heartbeat of the healthcare industry across China. In addition to its core distribution business, China National Medicines Corp Ltd. delves into the realm of medical device distribution and other healthcare-related services, diversifying its revenue streams. A significant portion of its income comes from partnerships and agreements with international pharmaceutical behemoths, allowing it to import and distribute advanced medicines and technology within China. By capitalizing on these strategic alliances, the company not only bolsters its portfolio but also strengthens its market position. This symbiotic relationship with both domestic and global players underpins its financial performance, making China National Medicines not just a distributor but a pivotal gatekeeper in the evolving landscape of China's healthcare industry.

China National Medicines Corp Ltd Intrinsic Value
HIDDEN
Show

See Also

What is China National Medicines Corp Ltd's Research & Development?
Research & Development
-73.2m CNY

Based on the financial report for Sep 30, 2025, China National Medicines Corp Ltd's Research & Development amounts to -73.2m CNY.

What is China National Medicines Corp Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-3%

Over the last year, the Research & Development growth was -18%. The average annual Research & Development growth rates for China National Medicines Corp Ltd have been -7% over the past three years , -3% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett